ProBioGen: Selected partner

ProBioGen’s innovative technologies and expertise make it a key partner for advancing biopharmaceutical research and development. With a strong focus on cell line engineering, process development, and GMP manufacturing, ProBioGen supports a wide range of applications from vaccine production to therapeutic antibody development. Our collaboration with ProBioGen allows us to incorporate their GlymaxX® technology in our recombinant antibody expression services.

Key facts

• Specialization: Cell line engineering, process development, GMP manufacturing 
• Technology: GlymaxX®, viral vector technologies, DirectedLuck® and more
• Services: Biopharmaceutical manufacturing, process development, cell-based assays, and others
• Website: www.probiogen.de

About ProBiogen

ProBioGen is a renowned Contract Development and Manufacturing Organization (CDMO) based in Berlin, Germany. They specialize in fields like cell line engineering, process development, and GMP manufacturing.

ProBioGen’s proprietary GlymaxX® technology is designed to produce afucosylated antibodies, which demonstrate higher Antibody-Dependent Cellular Cytotoxicity (ADCC), leading to enhanced therapeutic efficacy against tumor cells and infections.

Unlock the full potential of your research with ProBioGen and evitria

Through the strategic partnership with ProBioGen, evitria is equipped to offer superior afucosylated antibodies utilizing ProBioGen’s innovative GlymaxX® technology.

This partnership combines ProBioGen’s advanced afucosylation platform, which enhances antibody efficacy by boosting ADCC (Antibody-Dependent Cellular Cytotoxicity), with evitria’s expertise in CHO cell-based transient expression systems.